A pharmaceutical enterprise headquartered in Beijing, China has set up a biotech subsidiary in Massachusetts and is actively seeking cutting-edge life science technologies around the world. The firm makes equity investments of US$2-10 million in Seed to Series B stage companies, while later stages up to pre-IPO may also be considered. For overseas deals, the firm prefers to co-invest with top-tier lead investors. The firm is looking for opportunities across the globe.
The firm is looking for technologies across biopharmaceuticals, medical devices, and healthcare services that are a strategic fit with its portfolio. The firm is most interested in innovative platform technology in small molecule or biologic therapeutics targeting large disease markets in China. The firm considers early-stage companies from seed to Series B stage.
The firm seeks experienced management teams backed by strong, reputable VC firms. The firm typically requests board representation post-investment. The firm prefers to retain China rights, but this is not a requirement for investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org